- Home
- NDLS vs IGC Comparison
NDLS vs IGC Comparison
Compare NDLS & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- IGC
- Stock Information
- Founded
- NDLS 1995
- IGC 2005
- Country
- NDLS United States
- IGC United States
- Employees
- NDLS N/A
- IGC N/A
- Industry
- NDLS Restaurants
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- NDLS Consumer Discretionary
- IGC Health Care
- Exchange
- NDLS Nasdaq
- IGC Nasdaq
- Market Cap
- NDLS 33.2M
- IGC 39.8M
- IPO Year
- NDLS 2013
- IGC N/A
- Fundamental
- Price
- NDLS $0.67
- IGC $0.42
- Analyst Decision
- NDLS Buy
- IGC Strong Buy
- Analyst Count
- NDLS 2
- IGC 2
- Target Price
- NDLS $3.00
- IGC $4.00
- AVG Volume (30 Days)
- NDLS 177.0K
- IGC 1.3M
- Earning Date
- NDLS 11-05-2025
- IGC 11-11-2025
- Dividend Yield
- NDLS N/A
- IGC N/A
- EPS Growth
- NDLS N/A
- IGC N/A
- EPS
- NDLS N/A
- IGC N/A
- Revenue
- NDLS $494,752,000.00
- IGC $1,327,000.00
- Revenue This Year
- NDLS $1.19
- IGC $15.26
- Revenue Next Year
- NDLS N/A
- IGC $3.41
- P/E Ratio
- NDLS N/A
- IGC N/A
- Revenue Growth
- NDLS N/A
- IGC 24.95
- 52 Week Low
- NDLS $0.55
- IGC $0.25
- 52 Week High
- NDLS $1.74
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- NDLS 42.58
- IGC 53.17
- Support Level
- NDLS $0.66
- IGC $0.38
- Resistance Level
- NDLS $0.71
- IGC $0.47
- Average True Range (ATR)
- NDLS 0.03
- IGC 0.03
- MACD
- NDLS 0.01
- IGC -0.00
- Stochastic Oscillator
- NDLS 30.88
- IGC 38.00
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.